Fibromodulin (FMOD) is an extracellular matrix protein, it was recently proposed to be a novel tumor associated antigen (TAA) in B-cell chronic lymphocytic leukemia and it was found to be one of the most overexpressed genes in CLL. In this study, using reverse transcription-polymerase chain reaction (RT-PCR), fibromodulin gene was found to be expressed in 46% of patients with B-CLL in comparison to control group which was 0% (P value 0.006). There were significant relations between fibomodulin expression and some clinical and laboratory data such as lymphadenopathy, splenomegaly, hepatomegaly, lower hemoglobin level, lower RBCs count and lower platelet count. The reason for the expression of fibromodulin in B-CLL is unknown. Understanding the biological function of fibromodulin in B-CLL is critical because this molecule may be involved in the pathophysiology of B-CLL and may be used as a target for therapeutic intervention.